Pew Urges Greater State Investment in Evidence-Based Opioid Treatments

Letter to U.S. House committee says improved access to medication is critical for managing crisis

Pew Urges Greater State Investment in Evidence-Based Opioid Treatments

On Oct. 7, The Pew Charitable Trusts’ substance use prevention and treatment initiative submitted a letter to the U.S. House of Representatives Energy and Commerce Committee requesting that it encourage states to make long-term investments in evidence-based treatment.

Less than one-quarter of publicly funded treatment programs offer any U.S. Food and Drug Administration-approved medications for opioid use disorder (OUD), despite evidence of their effectiveness. Only 1 in 4 Americans with OUD receives any kind of care. The letter recommends that Congress prioritize access to expanded treatment—through mechanisms such as medication units and hub-and-spoke models—to help reduce fatal opioid overdoses.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.